U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Raritan Pharmaceuticals, Inc. - 516099 - 03/12/2018
  1. Warning Letters

CLOSEOUT LETTER

Raritan Pharmaceuticals, Inc. MARCS-CMS 516099 —

Recipient:
Raritan Pharmaceuticals, Inc.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
FAX: (973) 331-4969 
 
 

March 12, 2018

VIA UPS Next Day Air
Dr. Vin K. Nayak
President
Raritan Pharmaceuticals, Inc.
8 Joanna Ct.
East Brunswick, New Jersey 08816

Dear Dr. Nayak:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 17-NWJ-09, dated June 20, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and it implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Liatte Krueger Closs
Compliance Officer
OPQO/PHRM1-CB 

Back to Top